Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Liver Diseases Therapeutics Market Through 2034?
The market size for therapeutics in liver disease has seen robust growth in recent years. It is projected to expand from $14.16 billion in 2024 to $15.18 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. This growth during the historical period is largely due to the high incidence of liver diseases, patterns of alcohol consumption, advancements in diagnostic methods, prevalence of obesity and metabolic syndrome, awareness and screening initiatives, and governmental strategies for controlling hepatitis.
In the coming years, the market size for liver diseases therapeutics is projected to experience significant growth. It is predicted to hit $22.08 billion in 2029, with a compound annual growth rate (CAGR) of 9.8%. This growth over the forecast period is due to factors like precision medicine approaches, progress in RNA therapeutics, efforts towards fibrosis treatments, advocacy and support groups for patients, development of vaccines for hepatitis, and regulatory backing for orphan drugs. Key trends in the forecast period encompass advancements in hepatitis C treatment, the development of innovative therapies for liver fibrosis, the exploration of immunotherapies, telemedicine and remote monitoring, and an emphasis on nutritional interventions.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Liver Diseases Therapeutics Market?
The escalating occurrence of liver ailments is anticipated to fuel the enlargement of the liver disease therapeutics market in the future. Liver disease refers to any disorder that impacts the liver. These therapeutics assist in managing liver diseases through a variety of treatments. For instance, in April 2024, as reported by the Office for Health Improvement and Disparities, a government department based in the UK, the death rate from liver disease in individuals younger than 75 years in England increased to 21.4 per 100,000 population in 2022. Males accounted for 6,664 premature deaths, while females experienced 3,929 premature deaths. Consequently, the amplified prevalence of liver diseases is fuelling the expansion of the liver disease therapeutics market.
Which Primary Segments of the Liver Diseases Therapeutics Market Are Driving Growth and Industry Transformations?
The liver diseases therapeuticsmarket covered in this report is segmented –
1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer
2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids
3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
Subsegments:
1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver
3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Liver Diseases Therapeutics Market?# Market?
North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Liver Diseases Therapeutics Market?
The prominence of strategic alliances is a rising trend in the liver disease therapeutics market. Various major players in the liver disease treatment field are partaking in collaborations to fortify their market stance. An example of such collaboration took place in January 2022 between Aligos Therapeutics Inc., an American clinical-stage biopharmaceutical firm, and Merck & Co, a company also from the US that operates in the realm of liver disease therapeutics. Their cooperation is aimed at the discovery and development of oligonucleotide therapies for non-alcoholic steatohepatitis.
View the full report here:
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
What Parameters Are Used to Define the Liver Diseases Therapeutics Market?
Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses, including hepatitis A, B, and C. Liver disease therapeutics are essential for enhancing the quality of life for those impacted by liver conditions and alleviating the overall strain of liver disease on healthcare systems.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7969
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
